- Home
- CSR vs AVBP Comparison
CSR vs AVBP Comparison
Compare CSR & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSR
- AVBP
- Stock Information
- Founded
- CSR 1970
- AVBP 2021
- Country
- CSR United States
- AVBP United States
- Employees
- CSR N/A
- AVBP N/A
- Industry
- CSR Real Estate Investment Trusts
- AVBP
- Sector
- CSR Real Estate
- AVBP
- Exchange
- CSR Nasdaq
- AVBP NYSE
- Market Cap
- CSR 1.0B
- AVBP 862.8M
- IPO Year
- CSR N/A
- AVBP 2024
- Fundamental
- Price
- CSR $58.83
- AVBP $22.05
- Analyst Decision
- CSR Buy
- AVBP Strong Buy
- Analyst Count
- CSR 8
- AVBP 8
- Target Price
- CSR $72.13
- AVBP $38.38
- AVG Volume (30 Days)
- CSR 128.0K
- AVBP 440.3K
- Earning Date
- CSR 08-04-2025
- AVBP 08-13-2025
- Dividend Yield
- CSR 5.21%
- AVBP N/A
- EPS Growth
- CSR N/A
- AVBP N/A
- EPS
- CSR N/A
- AVBP N/A
- Revenue
- CSR $263,570,000.00
- AVBP N/A
- Revenue This Year
- CSR $4.85
- AVBP $85.82
- Revenue Next Year
- CSR $3.69
- AVBP N/A
- P/E Ratio
- CSR N/A
- AVBP N/A
- Revenue Growth
- CSR 2.19
- AVBP N/A
- 52 Week Low
- CSR $54.13
- AVBP $15.47
- 52 Week High
- CSR $76.16
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- CSR 36.37
- AVBP 50.39
- Support Level
- CSR $59.40
- AVBP $21.27
- Resistance Level
- CSR $60.61
- AVBP $22.39
- Average True Range (ATR)
- CSR 1.10
- AVBP 1.09
- MACD
- CSR -0.12
- AVBP 0.05
- Stochastic Oscillator
- CSR 4.90
- AVBP 65.36
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.